Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

TIGER: the gene expression regulatory variation landscape of human pancreatic islets

  • Alonso, Lorena
  • Ferrer, Jorge
  • Torrents, David
Genome-wide association studies (GWASs) identified hundreds of signals associated with type 2 diabetes (T2D). To gain insight into their underlying molecular mechanisms, we have created the translational human pancreatic islet genotype tissue-expression resource (TIGER), aggregating >500 human islet genomic datasets from five cohorts in the Horizon 2020 consortium T2DSystems. We impute genotypes using four reference panels and meta-analyze cohorts to improve the coverage of expression quantitative trait loci (eQTL) and develop a method to combine allele-specific expression across samples (cASE). We identify >1 million islet eQTLs, 53 of which colocalize with T2D signals. Among them, a low-frequency allele that reduces T2D risk by half increases CCND2 expression. We identify eight cASE colocalizations, among which we found a T2D-associated SLC30A8 variant. We make all data available through the TIGER portal (http://tiger.bsc.es), which represents a comprehensive human islet genomic data resource to elucidate how genetic variation affects islet function and translates into therapeutic insight and precision medicine for T2D., This work has been supported by the European Union’s Horizon 2020 research and innovation program T2Dsystems under grant agreement no. 667191. L.A. was supported by grant BES-2017-081635 of the Severo Ochoa Program, awarded by the Spanish government. I.M. was supported by the FJCI-2017-31878 Juan de la Cierva grant, awarded by the Spanish government. Work in the Cnop and Eizirik labs was further supported by the Fonds National de la Recherche Scientifique (FNRS), the Brussels Region Innoviris project DiaType, and the Walloon Region SPW-EER Win2Wal project BetaSource, Belgium. D.L.E. is supported by a grant from the Welbio–FNRS, Belgium. P.M., L.G., D.L.E., and M.C. are supported by the Innovative Medicines Initiative 2 Joint Undertaking Rhapsody, under grant agreement no. 115881, which is supported by the European Union’s Horizon 2020 research and innovation programme, EFPIA and the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097. J.M.M. is supported by American Diabetes Association Innovative and Clinical Translational Award 1-19-ICTS-068. J.C. is supported by an Expanding Excellence in England Award from Research England. H.M., J.L.S.E., and L.E. are supported by the Swedish Strategic Research Foundation (IRC15-0067). A.L.G. is a Wellcome Trust Senior Fellow in Basic Biomedical Science. This work was funded in Oxford and Stanford by the Wellcome Trust (095101, 200837, 106130, and 203141 [all to A.L.G.]) and the NIH (U01-DK105535 and U01-DK085545 [A.L.G.]). The research was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (A.L.G.). I.M.-E. was supported by the EFDS/Novo Nordisk Rising Star Programme. Work in the Ferrer lab was supported by the Imperial College London Research Computing Service, the NIHR Imperial BRC, and the Centre for Genomic Regulation (CRG) genomics facility, and grants from Ministerio de Ciencia e Innovación (BFU2014-54284-R and RTI2018-095666-B-I00), the Medical Research Council (MR/L02036X/1), the Wellcome Trust Senior Investigator Award (WT101033), and the European Research Council Advanced Grant (789055)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes

  • Miguel Escalada, Irene
  • Bonàs-Guarch, Silvia
  • Mendieta Esteban, Julen, 1992-
  • Atla, Goutham
  • Farabella, Irene
  • Morgan, Claire C.
  • García-Hurtado, Javier
  • Morán, Ignasi
  • Torrents, David
  • Mercader Bigas, Josep Maria
  • Marti-Renom, Marc A.
  • Ferrer, Jorge
Genetic studies promise to provide insight into the molecular mechanisms underlying type 2 diabetes (T2D). Variants associated with T2D are often located in tissue-specific enhancer clusters or super-enhancers. So far, such domains have been defined through clustering of enhancers in linear genome maps rather than in three-dimensional (3D) space. Furthermore, their target genes are often unknown. We have created promoter capture Hi-C maps in human pancreatic islets. This linked diabetes-associated enhancers to their target genes, often located hundreds of kilobases away. It also revealed >1,300 groups of islet enhancers, super-enhancers and active promoters that form 3D hubs, some of which show coordinated glucose-dependent activity. We demonstrate that genetic variation in hubs impacts insulin secretion heritability, and show that hub annotations can be used for polygenic scores that predict T2D risk driven by islet regulatory variants. Human islet 3D chromatin architecture, therefore, provides a framework for interpretation of T2D genome-wide association study (GWAS) signals., This research was supported by the National Institute for Health Research Imperial Biomedical Research Centre. Work was funded by grants from the Wellcome Trust (nos. WT101033 to J.F. and WT205915 to I.P.), Horizon 2020 (Research and Innovation Programme nos. 667191, to J.F., 633595, to I.P., and 676556, to M.A.M.-R.; Marie Sklodowska-Curie 658145, to I.M.-E., and 43062 ZENCODE, to G.A.), European Research Council (nos. 789055, to J.F., and 609989, to M.A.M.-R.). Marató TV3 (no. 201611, to J.F. and M.A.M.-R.), Ministerio de Ciencia Innovación y Universidades (nos. BFU2014-54284-R, RTI2018-095666, to J.F., BFU2017-85926-P, to M.A.M.-R., IJCI-2015-23352, to I.F.), AGAUR (to M.A.M.-R.). UK Medical Research Council (no. MR/L007150/1, to P.F., MR/L02036X/1 to J.F.), World Cancer Research Fund (WCRF UK, to I.P.) and World Cancer Research Fund International (no. 2017/1641 to I.P.), Biobanking and Biomolecular Resources Research Infrastructure (nos. BBMRI-NL, NWO 184.021.007, to I.O.F.). Work in IDIBAPS, CRG and CNAG was supported by the CERCA Programme, Generalitat de Catalunya and Centros de Excelencia Severo Ochoa (no. SEV-2012-0208). Human islets were provided through the European islet distribution program for basic research supported by JDRF (no. 3-RSC-2016-160-I-X). We thank N. Ruiz-Gomez for technical assistance; R. L. Fernandes, T. Thorne (University of Reading) and A. Perdones-Montero (Imperial College London) for helpful discussions regarding Machine Learning approaches; B. Lenhard and M. Merkenschlager (London Institute of Medical Sciences, Imperial College London), F. Müller (University of Birmingham) and J. L. Gómez-Skarmeta (Centro Andaluz de Biología del Desarrollo) for critical comments on the draft; the CRG Genomics Unit; and the Imperial College High Performance Computing Service.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

An integrated multi-omics approach identifies the landscape of interferon-α-mediated responses of human pancreatic beta cells

  • Colli, Maikel Luis
  • Ramos-Rodríguez, Mireia
  • Raurell Vila, Helena
  • Pasquali, Lorenzo
  • Eizirik, Décio L.
Interferon-α (IFNα), a type I interferon, is expressed in the islets of type 1 diabetic individuals, and its expression and signaling are regulated by T1D genetic risk variants and viral infections associated with T1D. We presently characterize human beta cell responses to IFNα by combining ATAC-seq, RNA-seq and proteomics assays. The initial response to IFNα is characterized by chromatin remodeling, followed by changes in transcriptional and translational regulation. IFNα induces changes in alternative splicing (AS) and first exon usage, increasing the diversity of transcripts expressed by the beta cells. This, combined with changes observed on protein modification/degradation, ER stress and MHC class I, may expand antigens presented by beta cells to the immune system. Beta cells also up-regulate the checkpoint proteins PDL1 and HLA-E that may exert a protective role against the autoimmune assault. Data mining of the present multi-omics analysis identifies two compound classes that antagonize IFNα effects on human beta cells., This work was supported by grants from the Fonds National de la Recherche Scientifique (FNRS), Welbio CR-2015A-06 and CR-2019C-04, Belgium; the Horizon 2020 Program, T2Dsystems (GA667191); the National Institutes of Health, NIH-NIDDK-HIRN Consortium 1UC4DK104166-01 and Innovate2CureType1 - Dutch Diabetes Research Fundation (DDRF). D.L.E. and P.M. have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 115797 (INNODIA). This Joint Undertaking receives support from the Union’s Horizon 2020 research and innovation programme and “EFPIA”, “JDRF” and “The Leona M. and Harry B. Helmsley Charitable Trust”. The DiViD study is funded by The South-Eastern Norway Regional Health Authority (grant to K.D.-J.), the Novo Nordisk Foundation (grant to K.D.-J.), and through the PEVNET (Persistent Virus Infection in Diabetes Network) Study Group funded by the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant Agreement Number 261441 PEVNET. Additional support was from a JDRF Career Development Award (5-CDA-2014-221-A-N) to S.J.R., a JDRF research grant awarded to the network of Pancreatic Organ Donors – Virus (nPOD-V) consortium (JDRF 25-2012-516); an MRC Project Grant MR/P010695/1 awarded to S.J.R. and N.G.M., a studentship grant from the Norman Family Trust (to S.J.R. and N.G.M.), a Spanish Ministry of Economy and Competiveness (SAF2017-86242-R to L.P.) and Marató TV3 (201624.10 to L.P.). L.P. is a recipient of a Ramon y Cajal contract from the Spanish Ministry of Economy and Competitiveness (RYC-2013-12864) and M.R. is supported by an FI Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) PhD fellowship.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Genetic regulation of RNA splicing in human pancreatic islets

  • Atla, Goutham
  • Bonàs-Guarch, Silvia
  • Cuenca-Ardura, Mirabai
  • Beucher, Anthony
  • Crouch, Daniel J.M.
  • García-Hurtado, Javier
  • Moran, Ignasi
  • T2DSystems Consortium
  • Irimia Martínez, Manuel
  • Prasad, Rashmi B.
  • Gloyn, Anna L.
  • Marselli, Lorella
  • Suleiman, Mara
  • Berney, Thierry
  • Koning, Eelco J.P. de
  • Kerr-Conte, Julie
  • Pattou, Francois
  • Todd, John A.
  • Piemonti, Lorenzo
  • Ferrer, Jorge
Background: Non-coding genetic variants that influence gene transcription in pancreatic islets play a major role in the susceptibility to type 2 diabetes (T2D), and likely also contribute to type 1 diabetes (T1D) risk. For many loci, however, the mechanisms through which non-coding variants influence diabetes susceptibility are unknown. Results: We examine splicing QTLs (sQTLs) in pancreatic islets from 399 human donors and observe that common genetic variation has a widespread influence on the splicing of genes with established roles in islet biology and diabetes. In parallel, we profile expression QTLs (eQTLs) and use transcriptome-wide association as well as genetic co-localization studies to assign islet sQTLs or eQTLs to T2D and T1D susceptibility signals, many of which lack candidate effector genes. This analysis reveals biologically plausible mechanisms, including the association of T2D with an sQTL that creates a nonsense isoform in ERO1B, a regulator of ER-stress and proinsulin biosynthesis. The expanded list of T2D risk effector genes reveals overrepresented pathways, including regulators of G-protein-mediated cAMP production. The analysis of sQTLs also reveals candidate effector genes for T1D susceptibility such as DCLRE1B, a senescence regulator, and lncRNA MEG3. Conclusions: These data expose widespread effects of common genetic variants on RNA splicing in pancreatic islets. The results support a role for splicing variation in diabetes susceptibility, and offer a new set of genetic targets with potential therapeutic benefit., This research was supported by Ministerio de Ciencia e Innovación (BFU2014-54284-R, RTI2018-095666-B-I00), Medical Research Council (MR/L02036X/1), a Wellcome Trust Senior Investigator Award (WT101033), European Research Council Advanced Grant (789055), EU Horizon 2020 TDSystems (667191), ESPACE (874710), and Marie Sklodowska-Curie (643062, ZENCODE). S.B.G was supported by a Juan de la Cierva postdoctoral fellowship (MINECO; FJCI-2017-32090). M.C.A was supported by a Boehringer Ingelheim Fonds PhD fellowship. Work in CRG was supported by the CERCA Programme, Generalitat de Catalunya, Centro de Excelencia Severo Ochoa (CEX2020-001049), and support of the Spanish Ministry of Science and Innovation to the EMBL partnership. Work in Imperial College was supported by NIHR Imperial Biomedical Research Centre. M.I. was supported by a European Research Council consolidator award (101002275). D.J.M.C. and J.A.T. were supported by JDRF grants 9-2011-253, 5-SRA-2015-130-A-N, 4- SRA-2017-473-A-N, and Wellcome grants 091157/Z/10/Z and 107212/Z/15/Z, to the Diabetes and Inflammation Laboratory, Oxford, as well as the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and NIHR Oxford Biomedical Research Centre, and Wellcome Trust Core Award grant 203141/Z/16/Z. D.M.J.C analysis with the UK Biobank Resource was conducted under Application 31295. A.L.G. is a Wellcome Senior Fellow in Basic Biomedical Science and was supported by the Wellcome Trust (095101, 200837, 106130, 203141), the NIDDK (U01DK105535 and UM1 DK126185), and the Oxford NIHR Biomedical Research Centre.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Pancreatic microexons regulate islet function and glucose homeostasis

  • Juan-Mateu, Jonàs
  • Bajew, Simon, 1994-
  • Miret-Cuesta, Marta
  • Iñiguez, Luis P.
  • Lopez-Pascual, Amaya
  • Bonnal, Sophie
  • Atla, Goutham
  • Bonàs-Guarch, Silvia
  • Ferrer, Jorge
  • Valcárcel, J. (Juan)
  • Irimia Martínez, Manuel
Pancreatic islets control glucose homeostasis by the balanced secretion of insulin and other hormones, and their abnormal function causes diabetes or hypoglycaemia. Here we uncover a conserved programme of alternative microexons included in mRNAs of islet cells, particularly in genes involved in vesicle transport and exocytosis. Islet microexons (IsletMICs) are regulated by the RNA binding protein SRRM3 and represent a subset of the larger neural programme that are particularly sensitive to SRRM3 levels. Both SRRM3 and IsletMICs are induced by elevated glucose levels, and depletion of SRRM3 in human and rat beta cell lines and mouse islets, or repression of particular IsletMICs using antisense oligonucleotides, leads to inappropriate insulin secretion. Consistently, mice harbouring mutations in Srrm3 display defects in islet cell identity and function, leading to hyperinsulinaemic hypoglycaemia. Importantly, human genetic variants that influence SRRM3 expression and IsletMIC inclusion in islets are associated with fasting glucose variation and type 2 diabetes risk. Taken together, our data identify a conserved microexon programme that regulates glucose homeostasis., We thank B. Banfi (University of Iowa) for kindly sharing the Srrm3 gene-trapped mouse line with us; M. Ángel Maestro for excellent technical advice on multiple protocols related to the study of Srrm3 mutant mice; J. Permanyer and C. Rodriguez for help with mouse genotyping; D. Balboa, I. Miguel-Escalada and E. Bernardo, as well as members of the M.I. and J.V. groups for constant scientific discussion; A. Gohr for assistance on bioinformatic analyses; S. Taylor (University of Manchester) for kindly sharing the HeLa Flp-In T-Rex cell line with us; and CRG Genomics and Advanced Light Microscopy Units for the RNA-seq and microscopy services. The research has been funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (ERC-StG-LS2-637591 and ERCCoG-LS2-101002275 to M.I., ERC-AdG-LS2-670146 to J.V., and ERC-AdG-LS4-789055 to J.F.), EU Horizon 2020 TDSystems (667191) to J.F., la Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR20/52400008 to M.I., an EFSD award supported by EFSD/Lilly European Diabetes Research Programme, the Spanish Ministry of Science and Innovation (BFU-2017-89308-P to J.V., BFU-2017-89201-P to M.I. and RTI2018-095666-B-I00 to J.F.) and the ‘Centro de Excelencia Severo Ochoa’ (CEX2020-001049). G.A. was supported by the Marie Skłodowska-Curie project ZENCODE-ITN (No. 643062). S.B.-G. was supported by a Juan de la Cierva postdoctoral fellowship (MINECO; FJCI-2017-32090). J.J.-M. was supported by the Beatriu de Pinós Programme and the Ministry of Research and Universities of the Government of Catalonia, and a Marie Skłodowska-Curie Individual Fellowship from the European Union’s Horizon 2020 research and innovation programme (MSCA-IF-2019-841758; http://ec.europa.eu/).
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

DEXI, a candidate gene for type 1 diabetes, modulates rat and human pancreatic beta cell inflammation via regulation of the type I IFN/STAT signalling pathway

  • Dos Santos, Reinaldo S.
  • Marroquí, Laura
  • Velayos Gainza, Teresa
  • Olazagoitia Garmendia, Ane
  • Jauregi Miguel, Amaia
  • Castellanos Rubio, Ainara
  • Eizirik, Decio L.
  • Castaño González, Luis Antonio
  • Santín Gómez, Izortze
Aims/hypothesis: The initial stages of type 1 diabetes are characterized by an aberrant islet inflammation that is in part regulated by the interaction between type 1 diabetes susceptibility genes and environmental factors. Chromosome 16p13 is associated with type 1 diabetes and CLEC16A has been considered the etiologic gene in the region. However, recent gene expression analysis indicates that SNPs in CLEC16A modulate the expression of a neighbouring gene with unknown function named DEXI. We presently evaluated the role of DEXI in beta cell responses to “danger signals” and determined the mechanisms involved. Methods: Functional studies based on silencing or overexpression of DEXI were performed in rat and human pancreatic beta cells. Viral double-stranded RNA-driven beta cell inflammation and apoptosis were evaluated by RT-PCR, western blot and luciferase assays. Results: DEXI-silenced beta cells exposed to double-stranded RNA (PIC; a by-product of viral replication) showed reduced STAT1 activation and lower production of pro-inflammatory chemokines that was preceded by a reduction in IFN expression. Exposure to PIC increased chromatin-bound DEXI and IFN promoter activity. This effect on IFN promoter was inhibited in DEXI-silenced betacells, suggesting that DEXI is implicated in the regulation of IFNtranscription. In a mirror image of knockdown experiments, DEXI overexpression led to increased STAT1 and pro-inflammatory chemokine expression. Conclusions: These observations support DEXI as the aetiological gene in the type 1 diabetes-associated 16p13 genomic region and provide the first indication of a link between this candidate gene and the regulation of local antiviral immune response in beta cells. Moreover, our results provide initial information on the function of DEXI., This work was supported by a Research Project Grant from the Basque Department of Health (2015111068), a Research Grant from Fundación de la Sociedad Española de Diabetes (FSED), the Horizon 2020 Program T2Dsystems (GA667191) and the NIH- NIDDK-HIRN Consortium 1UC4DK104166-01, USA. TV and AJM were supported by Predoctoral Fellowship grants from the UPV/EHU and the Basque Department of Education, respectively. AOG is supported by a Predoctoral Fellowship Grant from the Basque Department of Education. ACR is supported by an Ikerbasque Research Fellow grant. LM was supported by a Fonds National de la Recherche Scientifique postdoctoral fellowship. DLE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115797 (INNODIA). This Joint Undertaking
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes

  • Bonàs-Guarch, Silvia
  • Guindo-Martínez, M.
  • Miguel-Escalada, I.
  • Niels Grarup
  • Sebastian, David
  • Rodriguez-Fos, Elias
  • Sánchez, Friman
  • Planas-Fèlix, Mercè
  • Cortes-Sánchez, Paula
  • González, Santi
  • Timshel, Pascal
  • Pers, Tune H.
  • Morgan, Claire C.
  • Morán, Ignasi
  • Atla, Goutham
  • González, Juan R.
  • Puiggros, Montserrat
  • Martí, Jonathan
  • Andersson, Ehm A.
  • Díaz, Carlos
  • Badia, Rosa M.
  • Udler, Miriam
  • Leong, Aaron
  • Kaur, Varindepal
  • Flannick, Jason
  • Jørgensen, Torben
  • Linneberg, Allan
  • Jørgensen, Marit E.
  • Witte, Daniel R.
  • Christensen, Cramer
  • Brandslund, Ivan
  • Appel, Emil V.
  • Scott, Robert A.
  • Luan, Jian’an
  • Langenberg, Claudia
  • Wareham, Nicholas J.
  • Pedersen, Oluf
  • Zorzano, Antonio
  • Florez, Jose C.
  • Hansen, Torben
  • Ferrer, Jorge
  • Mercader, Josep Maria
  • Torrents, David
The reanalysis of existing GWAS data represents a powerful and cost-effective opportunity to gain insights into the genetics of complex diseases. By reanalyzing publicly available type 2 diabetes (T2D) genome-wide association studies (GWAS) data for 70,127 subjects, we identify seven novel associated regions, five driven by common variants (LYPLAL1, NEUROG3, CAMKK2, ABO, and GIP genes), one by a low-frequency (EHMT2), and one driven by a rare variant in chromosome Xq23, rs146662057, associated with a twofold increased risk for T2D in males. rs146662057 is located within an active enhancer associated with the expression of Angiotensin II Receptor type 2 gene (AGTR2), a modulator of insulin sensitivity, and exhibits allelic specific activity in muscle cells. Beyond providing insights into the genetics and pathophysiology of T2D, these results also underscore the value of reanalyzing publicly available data using novel genetic resources and analytical approaches., This work has been sponsored by the grant SEV-2011-00067 of Severo Ochoa Program, awarded by the Spanish Government. This work was supported by an EFSD/Lilly research fellowship. Josep M. Mercader was supported by Sara Borrell Fellowship from the Instituto Carlos III and Beatriu de Pinós fellowship from the Agency for Management of University and Research Grants (AGAUR). Sílvia Bonàs was FI-DGR Fellowship from FI-DGR 2013 from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya). This study makes use of data generated by the WTCCC. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113. This study also makes use of data generated by the UK10K Consortium, derived from samples from UK10K COHORT IMPUTATION (EGAS00001000713). A full list of the investigators who contributed to the generation of the data is available in www.UK10K.org. Funding for UK10K was provided by the Wellcome Trust under award WT091310. We acknowledge PRACE for awarding us to access MareNostrum supercomputer, based in Spain at Barcelona. The technical support group, particularly Pablo Ródenas and Jorge Rodríguez, from the Barcelona Supercomputing Center is gratefully acknowledged. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 667191. Mercè Planas-Fèlix is funded by the Obra Social Fundación la Caixa fellowship under the Severo Ochoa 2013 program. Work from Irene Miguel-Escalada, Ignasi Moran, Goutham Atla, and Jorge Ferrer was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre, the Wellcome Trust (WT101033), Ministerio de Economía y Competitividad (BFU2014-54284-R) and Horizon 2020 (667191). Irene Miguel-Escalada has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska–Curie grant agreement No 658145. We acknowledge Prof. Giulio Cossu (Institute of Inflammation and Repair, University of Manchester) for providing the muscle myoblast cell line. We also acknowledge the InterAct and SIGMA Type 2 Diabetes Consortia for access to the data to replicate the rs146662075 variant. A full list of the investigators of the SIGMA Type 2 Diabetes and the InterAct consortia is provided in Supplementary Notes 3 and 4. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk). This research has been conducted using the UK Biobank Resource (application number 16803). We also acknowledge Bianca C. Porneala, MS for his technical assistance in the collection and curation of the genotype and phenotype data from Partners Biobank. We also thank Marcin von Grotthuss for their support for uploading the summary statistics data to the Type 2 Diabetes Genetic Portal (AMP-T2D portal). Finally, we thank all the Computational Genomics group at the BSC for their helpful discussions and valuable comments on the manuscript., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

TIGER: The gene expression regulatory variation landscape of human pancreatic islets

  • Alonso, Lorena
  • Piron, Anthony
  • Morán, Ignasi
  • Guindo Martínez, Marta
  • Bonàs Guarch, Sílvia
  • Royo, Romina|||0000-0003-3493-0874
  • Puiggròs, Montserrat
  • Amela, Ramon
  • Mercader, Josep M.
  • Torrents, David
Genome-wide association studies (GWASs) identified hundreds of signals associated with type 2 diabetes (T2D). To gain insight into their underlying molecular mechanisms, we have created the translational human pancreatic islet genotype tissue-expression resource (TIGER), aggregating >500 human islet genomic datasets from five cohorts in the Horizon 2020 consortium T2DSystems. We impute genotypes using four reference panels and meta-analyze cohorts to improve the coverage of expression quantitative trait loci (eQTL) and develop a method to combine allele-specific expression across samples (cASE). We identify >1 million islet eQTLs, 53 of which colocalize with T2D signals. Among them, a low-frequency allele that reduces T2D risk by half increases CCND2 expression. We identify eight cASE colocalizations, among which we found a T2D-associated SLC30A8 variant. We make all data available through the TIGER portal (http://tiger.bsc.es), which represents a comprehensive human islet genomic data resource to elucidate how genetic variation affects islet function and translates into therapeutic insight and precision medicine for T2D., This work has been supported by the European Union’s Horizon 2020 research and innovation program T2Dsystems under grant agreement no. 667191 . L.A. was supported by grant BES-2017-081635 of the Severo Ochoa Program, awarded by the Spanish government . I.M. was supported by the FJCI-2017-31878 Juan de la Cierva grant, awarded by the Spanish government . Work in the Cnop and Eizirik labs was further supported by the Fonds National de la Recherche Scientifique (FNRS), the Brussels Region Innoviris project DiaType , and the Walloon Region SPW-EER Win2Wal project BetaSource, Belgium . D.L.E. is supported by a grant from the Welbio–FNRS , Belgium. P.M., L.G., D.L.E., and M.C. are supported by the Innovative Medicines Initiative 2 Joint Undertaking Rhapsody , under grant agreement no. 115881 , which is supported by the European Union’s Horizon 2020 research and innovation programme, EFPIA and the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097 . J.M.M. is supported by American Diabetes Association Innovative and Clinical Translational Award 1-19-ICTS-068 . J.C. is supported by an Expanding Excellence in England Award from Research England . H.M., J.L.S.E., and L.E. are supported by the Swedish Strategic Research Foundation ( IRC15-0067 ). A.L.G. is a Wellcome Trust Senior Fellow in Basic Biomedical Science. This work was funded in Oxford and Stanford by the Wellcome Trust ( 095101 , 200837 , 106130 , and 203141 [all to A.L.G.]) and the NIH ( U01-DK105535 and U01-DK085545 [A.L.G.]). The research was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (A.L.G.). I.M.-E. was supported by the EFDS/Novo Nordisk Rising Star Programme . Work in the Ferrer lab was supported by the Imperial College London Research Computing Service , the NIHR Imperial BRC , and the Centre for Genomic Regulation (CRG) genomics facility , and grants from Ministerio de Ciencia e Innovación ( BFU2014-54284-R and RTI2018-095666-B-I00 ), the Medical Research Council ( MR/L02036X/1 ), the Wellcome Trust Senior Investigator Award ( WT101033 ), and the European Research Council Advanced Grant ( 789055 ). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. The technical support group from the Barcelona Supercomputing Center is gratefully acknowledged. Finally, we thank the entire Computational Genomics group at the BSC for their helpful discussions and valuable comments on the manuscript. We also acknowledge Cristian Opi and Laia Codó from the Barcelona Supercomputing Center for excellent website design and allocation of technical support and Isabelle Millard and Anyishaï Musuaya from the ULB Center for Diabetes Research for excellent technical and experimental support., Peer Reviewed, "Article signat per 30 autors/es: Lorena Alonso, Anthony Piron, Ignasi Morán, Marta Guindo-Martínez, Sílvia Bonàs-Guarch, Goutham Atla, Irene Miguel-Escalada, Romina Royo, Montserrat Puiggròs, Xavier Garcia-Hurtado, Mara Suleiman, Lorella Marselli, Jonathan L.S. Esguerra, Jean-Valéry Turatsinze, Jason M. Torres, Vibe Nylander, Ji Chen, Lena Eliasson, Matthieu Defrance, Ramon Amela, MAGIC24, Hindrik Mulder, Anna L. Gloyn, Leif Groop, Piero Marchetti, Decio L. Eizirik, Jorge Ferrer, Josep M. Mercader, Miriam Cnop, David Torrents"
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes

  • Bonàs-Guarch, Sílvia
  • Guindo-Martínez, Marta
  • Miguel-Escalada, Irene
  • Grarup, Niels
  • Sebastian, David
  • Rodriguez-Fos, Elias
  • Sánchez, Friman
  • Planas-Fèlix, Mercè
  • Cortes-Sánchez, Paula
  • González, Santi
  • Timshel, Pascal
  • Pers, Tune H.
  • Morgan, Claire C.
  • Moran, Ignasi
  • Atla, Goutham
  • González, Juan R.
  • Puiggros, Montserrat
  • Martí, Jonathan
  • Andersson, Ehm A.
  • Díaz, Carlos
  • Badia Sala, Rosa Maria|||0000-0003-2941-5499
  • Udler, Miriam
  • Leong, Aaron
  • Kaur, Varindepal
  • Flannick, Jason
  • Jorgensen, Torben
  • Linneberg, Allan
  • Jorgensen, Marit E.
  • Witte, Daniel R.
  • Christensen, Cramer
  • Brandslund, Ivan
  • Appel, Emil V.
  • Scott, Robert A.
  • Luan, Jian' an
  • Langenberg, Claudia
  • Wareham, Nicholas J.
  • Pedersen, Oluf
  • Zorzano, Antonio
  • Florez, Jose C.
  • Hansen, Torben
  • Ferrer, Jorge
  • Mercader, Josep M.
  • Torrents, David
The reanalysis of existing GWAS data represents a powerful and cost-effective opportunity to gain insights into the genetics of complex diseases. By reanalyzing publicly available type 2 diabetes (T2D) genome-wide association studies (GWAS) data for 70,127 subjects, we identify seven novel associated regions, five driven by common variants (LYPLAL1, NEUROG3, CAMKK2, ABO, and GIP genes), one by a low-frequency (EHMT2), and one driven by a rare variant in chromosome Xq23, rs146662057, associated with a twofold increased risk for T2D in males. rs146662057 is located within an active enhancer associated with the expression of Angiotensin II Receptor type 2 gene (AGTR2), a modulator of insulin sensitivity, and exhibits allelic specific activity in muscle cells. Beyond providing insights into the genetics and pathophysiology of T2D, these results also underscore the value of reanalyzing publicly available data using novel genetic resources and analytical approaches., This work has been sponsored by the grant SEV-2011-00067 of Severo Ochoa Program, awarded by the Spanish Government. This work was supported by an EFSD/Lilly research fellowship. Josep M. Mercader was supported by Sara Borrell Fellowship from the Instituto Carlos III and Beatriu de Pinós fellowship from the Agency for Management of University and Research Grants (AGAUR). Sílvia Bonàs was FI-DGR Fellowship from FI-DGR 2013 from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya). This study makes use of data generated by the WTCCC. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113. This study also makes use of data generated by the UK10K Consortium, derived from samples from UK10K COHORT IMPUTATION (EGAS00001000713). A full list of the investigators who contributed to the generation of the data is available in www.UK10K.org. Funding for UK10K was provided by the Wellcome Trust under award WT091310. We acknowledge PRACE for awarding us to access MareNostrum supercomputer, based in Spain at Barcelona. The technical support group, particularly Pablo Ródenas and Jorge Rodríguez, from the Barcelona Supercomputing Center is gratefully acknowledged. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 667191. Mercè Planas-Fèlix is funded by the Obra Social Fundación la Caixa fellowship under the Severo Ochoa 2013 program. Work from Irene Miguel-Escalada, Ignasi Moran, Goutham Atla, and Jorge Ferrer was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre, the Wellcome Trust (WT101033), Ministerio de Economía y Competitividad (BFU2014-54284-R) and Horizon 2020 (667191). Irene Miguel-Escalada has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska–Curie grant agreement No 658145. We acknowledge Prof. Giulio Cossu (Institute of Inflammation and Repair, University of Manchester) for providing the muscle myoblast cell line. We also acknowledge the InterAct and SIGMA Type 2 Diabetes Consortia for access to the data to replicate the rs146662075 variant. A full list of the investigators of the SIGMA Type 2 Diabetes and the InterAct consortia is provided in Supplementary Notes 3 and 4. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk). This research has been conducted using the UK Biobank Resource (application number 16803). We also acknowledge Bianca C. Porneala, MS for his technical assistance in the collection and curation of the genotype and phenotype data from Partners Biobank. We also thank Marcin von Grotthuss for their support for uploading the summary statistics data to the Type 2 Diabetes Genetic Portal (AMP-T2D portal). Finally, we thank all the Computational Genomics group at the BSC for their helpful discussions and valuable comments on the manuscript., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genetic regulation of RNA splicing in human pancreatic islets

  • Atla, Goutham
  • Bonàs-Guarch, Silvia
  • Cuenca-Ardura, Mirabai
  • Beucher, Anthony
  • Crouch, Daniel J.M.
  • García-Hurtado, Javier
  • Moran, Ignasi
  • T2DSystems Consortium
  • Irimia Martínez, Manuel
  • Prasad, Rashmi B.
  • Gloyn, Anna L.
  • Marselli, Lorella
  • Suleiman, Mara
  • Berney, Thierry
  • Koning, Eelco J.P. de
  • Kerr-Conte, Julie
  • Pattou, Francois
  • Todd, John A.
  • Piemonti, Lorenzo
  • Ferrer, Jorge
Background: Non-coding genetic variants that influence gene transcription in pancreatic islets play a major role in the susceptibility to type 2 diabetes (T2D), and likely also contribute to type 1 diabetes (T1D) risk. For many loci, however, the mechanisms through which non-coding variants influence diabetes susceptibility are unknown. Results: We examine splicing QTLs (sQTLs) in pancreatic islets from 399 human donors and observe that common genetic variation has a widespread influence on the splicing of genes with established roles in islet biology and diabetes. In parallel, we profile expression QTLs (eQTLs) and use transcriptome-wide association as well as genetic co-localization studies to assign islet sQTLs or eQTLs to T2D and T1D susceptibility signals, many of which lack candidate effector genes. This analysis reveals biologically plausible mechanisms, including the association of T2D with an sQTL that creates a nonsense isoform in ERO1B, a regulator of ER-stress and proinsulin biosynthesis. The expanded list of T2D risk effector genes reveals overrepresented pathways, including regulators of G-protein-mediated cAMP production. The analysis of sQTLs also reveals candidate effector genes for T1D susceptibility such as DCLRE1B, a senescence regulator, and lncRNA MEG3. Conclusions: These data expose widespread effects of common genetic variants on RNA splicing in pancreatic islets. The results support a role for splicing variation in diabetes susceptibility, and offer a new set of genetic targets with potential therapeutic benefit., This research was supported by Ministerio de Ciencia e Innovación (BFU2014-54284-R, RTI2018-095666-B-I00), Medical Research Council (MR/L02036X/1), a Wellcome Trust Senior Investigator Award (WT101033), European Research Council Advanced Grant (789055), EU Horizon 2020 TDSystems (667191), ESPACE (874710), and Marie Sklodowska-Curie (643062, ZENCODE). S.B.G was supported by a Juan de la Cierva postdoctoral fellowship (MINECO; FJCI-2017-32090). M.C.A was supported by a Boehringer Ingelheim Fonds PhD fellowship. Work in CRG was supported by the CERCA Programme, Generalitat de Catalunya, Centro de Excelencia Severo Ochoa (CEX2020-001049), and support of the Spanish Ministry of Science and Innovation to the EMBL partnership. Work in Imperial College was supported by NIHR Imperial Biomedical Research Centre. M.I. was supported by a European Research Council consolidator award (101002275). D.J.M.C. and J.A.T. were supported by JDRF grants 9-2011-253, 5-SRA-2015-130-A-N, 4- SRA-2017-473-A-N, and Wellcome grants 091157/Z/10/Z and 107212/Z/15/Z, to the Diabetes and Inflammation Laboratory, Oxford, as well as the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and NIHR Oxford Biomedical Research Centre, and Wellcome Trust Core Award grant 203141/Z/16/Z. D.M.J.C analysis with the UK Biobank Resource was conducted under Application 31295. A.L.G. is a Wellcome Senior Fellow in Basic Biomedical Science and was supported by the Wellcome Trust (095101, 200837, 106130, 203141), the NIDDK (U01DK105535 and UM1 DK126185), and the Oxford NIHR Biomedical Research Centre.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

An integrated multi-omics approach identifies the landscape of interferon-α-mediated responses of human pancreatic beta cells

  • Colli, Maikel Luis
  • Ramos-Rodríguez, Mireia
  • Raurell Vila, Helena
  • Pasquali, Lorenzo
  • Eizirik, Décio L.
Interferon-α (IFNα), a type I interferon, is expressed in the islets of type 1 diabetic individuals, and its expression and signaling are regulated by T1D genetic risk variants and viral infections associated with T1D. We presently characterize human beta cell responses to IFNα by combining ATAC-seq, RNA-seq and proteomics assays. The initial response to IFNα is characterized by chromatin remodeling, followed by changes in transcriptional and translational regulation. IFNα induces changes in alternative splicing (AS) and first exon usage, increasing the diversity of transcripts expressed by the beta cells. This, combined with changes observed on protein modification/degradation, ER stress and MHC class I, may expand antigens presented by beta cells to the immune system. Beta cells also up-regulate the checkpoint proteins PDL1 and HLA-E that may exert a protective role against the autoimmune assault. Data mining of the present multi-omics analysis identifies two compound classes that antagonize IFNα effects on human beta cells., This work was supported by grants from the Fonds National de la Recherche Scientifique (FNRS), Welbio CR-2015A-06 and CR-2019C-04, Belgium; the Horizon 2020 Program, T2Dsystems (GA667191); the National Institutes of Health, NIH-NIDDK-HIRN Consortium 1UC4DK104166-01 and Innovate2CureType1 - Dutch Diabetes Research Fundation (DDRF). D.L.E. and P.M. have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 115797 (INNODIA). This Joint Undertaking receives support from the Union’s Horizon 2020 research and innovation programme and “EFPIA”, “JDRF” and “The Leona M. and Harry B. Helmsley Charitable Trust”. The DiViD study is funded by The South-Eastern Norway Regional Health Authority (grant to K.D.-J.), the Novo Nordisk Foundation (grant to K.D.-J.), and through the PEVNET (Persistent Virus Infection in Diabetes Network) Study Group funded by the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant Agreement Number 261441 PEVNET. Additional support was from a JDRF Career Development Award (5-CDA-2014-221-A-N) to S.J.R., a JDRF research grant awarded to the network of Pancreatic Organ Donors – Virus (nPOD-V) consortium (JDRF 25-2012-516); an MRC Project Grant MR/P010695/1 awarded to S.J.R. and N.G.M., a studentship grant from the Norman Family Trust (to S.J.R. and N.G.M.), a Spanish Ministry of Economy and Competiveness (SAF2017-86242-R to L.P.) and Marató TV3 (201624.10 to L.P.). L.P. is a recipient of a Ramon y Cajal contract from the Spanish Ministry of Economy and Competitiveness (RYC-2013-12864) and M.R. is supported by an FI Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) PhD fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pancreatic microexons regulate islet function and glucose homeostasis

  • Juan-Mateu, Jonàs
  • Bajew, Simon, 1994-
  • Miret-Cuesta, Marta
  • Iñiguez, Luis P.
  • Lopez-Pascual, Amaya
  • Bonnal, Sophie
  • Atla, Goutham
  • Bonàs-Guarch, Silvia
  • Ferrer, Jorge
  • Valcárcel, J. (Juan)
  • Irimia Martínez, Manuel
Pancreatic islets control glucose homeostasis by the balanced secretion of insulin and other hormones, and their abnormal function causes diabetes or hypoglycaemia. Here we uncover a conserved programme of alternative microexons included in mRNAs of islet cells, particularly in genes involved in vesicle transport and exocytosis. Islet microexons (IsletMICs) are regulated by the RNA binding protein SRRM3 and represent a subset of the larger neural programme that are particularly sensitive to SRRM3 levels. Both SRRM3 and IsletMICs are induced by elevated glucose levels, and depletion of SRRM3 in human and rat beta cell lines and mouse islets, or repression of particular IsletMICs using antisense oligonucleotides, leads to inappropriate insulin secretion. Consistently, mice harbouring mutations in Srrm3 display defects in islet cell identity and function, leading to hyperinsulinaemic hypoglycaemia. Importantly, human genetic variants that influence SRRM3 expression and IsletMIC inclusion in islets are associated with fasting glucose variation and type 2 diabetes risk. Taken together, our data identify a conserved microexon programme that regulates glucose homeostasis., We thank B. Banfi (University of Iowa) for kindly sharing the Srrm3 gene-trapped mouse line with us; M. Ángel Maestro for excellent technical advice on multiple protocols related to the study of Srrm3 mutant mice; J. Permanyer and C. Rodriguez for help with mouse genotyping; D. Balboa, I. Miguel-Escalada and E. Bernardo, as well as members of the M.I. and J.V. groups for constant scientific discussion; A. Gohr for assistance on bioinformatic analyses; S. Taylor (University of Manchester) for kindly sharing the HeLa Flp-In T-Rex cell line with us; and CRG Genomics and Advanced Light Microscopy Units for the RNA-seq and microscopy services. The research has been funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (ERC-StG-LS2-637591 and ERCCoG-LS2-101002275 to M.I., ERC-AdG-LS2-670146 to J.V., and ERC-AdG-LS4-789055 to J.F.), EU Horizon 2020 TDSystems (667191) to J.F., la Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR20/52400008 to M.I., an EFSD award supported by EFSD/Lilly European Diabetes Research Programme, the Spanish Ministry of Science and Innovation (BFU-2017-89308-P to J.V., BFU-2017-89201-P to M.I. and RTI2018-095666-B-I00 to J.F.) and the ‘Centro de Excelencia Severo Ochoa’ (CEX2020-001049). G.A. was supported by the Marie Skłodowska-Curie project ZENCODE-ITN (No. 643062). S.B.-G. was supported by a Juan de la Cierva postdoctoral fellowship (MINECO; FJCI-2017-32090). J.J.-M. was supported by the Beatriu de Pinós Programme and the Ministry of Research and Universities of the Government of Catalonia, and a Marie Skłodowska-Curie Individual Fellowship from the European Union’s Horizon 2020 research and innovation programme (MSCA-IF-2019-841758; http://ec.europa.eu/).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes

  • Miguel Escalada, Irene
  • Bonàs-Guarch, Silvia
  • Mendieta Esteban, Julen, 1992-
  • Atla, Goutham
  • Farabella, Irene
  • Morgan, Claire C.
  • García-Hurtado, Javier
  • Morán, Ignasi
  • Torrents, David
  • Mercader Bigas, Josep Maria
  • Marti-Renom, Marc A.
  • Ferrer, Jorge
Genetic studies promise to provide insight into the molecular mechanisms underlying type 2 diabetes (T2D). Variants associated with T2D are often located in tissue-specific enhancer clusters or super-enhancers. So far, such domains have been defined through clustering of enhancers in linear genome maps rather than in three-dimensional (3D) space. Furthermore, their target genes are often unknown. We have created promoter capture Hi-C maps in human pancreatic islets. This linked diabetes-associated enhancers to their target genes, often located hundreds of kilobases away. It also revealed >1,300 groups of islet enhancers, super-enhancers and active promoters that form 3D hubs, some of which show coordinated glucose-dependent activity. We demonstrate that genetic variation in hubs impacts insulin secretion heritability, and show that hub annotations can be used for polygenic scores that predict T2D risk driven by islet regulatory variants. Human islet 3D chromatin architecture, therefore, provides a framework for interpretation of T2D genome-wide association study (GWAS) signals., This research was supported by the National Institute for Health Research Imperial Biomedical Research Centre. Work was funded by grants from the Wellcome Trust (nos. WT101033 to J.F. and WT205915 to I.P.), Horizon 2020 (Research and Innovation Programme nos. 667191, to J.F., 633595, to I.P., and 676556, to M.A.M.-R.; Marie Sklodowska-Curie 658145, to I.M.-E., and 43062 ZENCODE, to G.A.), European Research Council (nos. 789055, to J.F., and 609989, to M.A.M.-R.). Marató TV3 (no. 201611, to J.F. and M.A.M.-R.), Ministerio de Ciencia Innovación y Universidades (nos. BFU2014-54284-R, RTI2018-095666, to J.F., BFU2017-85926-P, to M.A.M.-R., IJCI-2015-23352, to I.F.), AGAUR (to M.A.M.-R.). UK Medical Research Council (no. MR/L007150/1, to P.F., MR/L02036X/1 to J.F.), World Cancer Research Fund (WCRF UK, to I.P.) and World Cancer Research Fund International (no. 2017/1641 to I.P.), Biobanking and Biomolecular Resources Research Infrastructure (nos. BBMRI-NL, NWO 184.021.007, to I.O.F.). Work in IDIBAPS, CRG and CNAG was supported by the CERCA Programme, Generalitat de Catalunya and Centros de Excelencia Severo Ochoa (no. SEV-2012-0208). Human islets were provided through the European islet distribution program for basic research supported by JDRF (no. 3-RSC-2016-160-I-X). We thank N. Ruiz-Gomez for technical assistance; R. L. Fernandes, T. Thorne (University of Reading) and A. Perdones-Montero (Imperial College London) for helpful discussions regarding Machine Learning approaches; B. Lenhard and M. Merkenschlager (London Institute of Medical Sciences, Imperial College London), F. Müller (University of Birmingham) and J. L. Gómez-Skarmeta (Centro Andaluz de Biología del Desarrollo) for critical comments on the draft; the CRG Genomics Unit; and the Imperial College High Performance Computing Service.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

TIGER: the gene expression regulatory variation landscape of human pancreatic islets

  • Alonso, Lorena
  • Ferrer, Jorge
  • Torrents, David
Genome-wide association studies (GWASs) identified hundreds of signals associated with type 2 diabetes (T2D). To gain insight into their underlying molecular mechanisms, we have created the translational human pancreatic islet genotype tissue-expression resource (TIGER), aggregating >500 human islet genomic datasets from five cohorts in the Horizon 2020 consortium T2DSystems. We impute genotypes using four reference panels and meta-analyze cohorts to improve the coverage of expression quantitative trait loci (eQTL) and develop a method to combine allele-specific expression across samples (cASE). We identify >1 million islet eQTLs, 53 of which colocalize with T2D signals. Among them, a low-frequency allele that reduces T2D risk by half increases CCND2 expression. We identify eight cASE colocalizations, among which we found a T2D-associated SLC30A8 variant. We make all data available through the TIGER portal (http://tiger.bsc.es), which represents a comprehensive human islet genomic data resource to elucidate how genetic variation affects islet function and translates into therapeutic insight and precision medicine for T2D., This work has been supported by the European Union’s Horizon 2020 research and innovation program T2Dsystems under grant agreement no. 667191. L.A. was supported by grant BES-2017-081635 of the Severo Ochoa Program, awarded by the Spanish government. I.M. was supported by the FJCI-2017-31878 Juan de la Cierva grant, awarded by the Spanish government. Work in the Cnop and Eizirik labs was further supported by the Fonds National de la Recherche Scientifique (FNRS), the Brussels Region Innoviris project DiaType, and the Walloon Region SPW-EER Win2Wal project BetaSource, Belgium. D.L.E. is supported by a grant from the Welbio–FNRS, Belgium. P.M., L.G., D.L.E., and M.C. are supported by the Innovative Medicines Initiative 2 Joint Undertaking Rhapsody, under grant agreement no. 115881, which is supported by the European Union’s Horizon 2020 research and innovation programme, EFPIA and the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097. J.M.M. is supported by American Diabetes Association Innovative and Clinical Translational Award 1-19-ICTS-068. J.C. is supported by an Expanding Excellence in England Award from Research England. H.M., J.L.S.E., and L.E. are supported by the Swedish Strategic Research Foundation (IRC15-0067). A.L.G. is a Wellcome Trust Senior Fellow in Basic Biomedical Science. This work was funded in Oxford and Stanford by the Wellcome Trust (095101, 200837, 106130, and 203141 [all to A.L.G.]) and the NIH (U01-DK105535 and U01-DK085545 [A.L.G.]). The research was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (A.L.G.). I.M.-E. was supported by the EFDS/Novo Nordisk Rising Star Programme. Work in the Ferrer lab was supported by the Imperial College London Research Computing Service, the NIHR Imperial BRC, and the Centre for Genomic Regulation (CRG) genomics facility, and grants from Ministerio de Ciencia e Innovación (BFU2014-54284-R and RTI2018-095666-B-I00), the Medical Research Council (MR/L02036X/1), the Wellcome Trust Senior Investigator Award (WT101033), and the European Research Council Advanced Grant (789055)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes

  • Bonàs-Guarch, Sílvia
  • Guindo-Martínez, Marta
  • Miguel-Escalada, Irene
  • Grarup, Niels
  • Sebastian, David
  • Rodriguez-Fos, Elias
  • Sánchez, Friman
  • Planas-Fèlix, Mercè
  • Cortes-Sánchez, Paula
  • González, Santi
  • Timshel, Pascal
  • Pers, Tune H.
  • Morgan, Claire C.
  • Moran, Ignasi
  • Atla, Goutham
  • González, Juan R.
  • Puiggros, Montserrat
  • Martí, Jonathan
  • Andersson, Ehm A.
  • Díaz, Carlos
  • Badia Sala, Rosa Maria
  • Udler, Miriam
  • Leong, Aaron
  • Kaur, Varindepal
  • Flannick, Jason
  • Jorgensen, Torben
  • Linneberg, Allan
  • Jorgensen, Marit E.
  • Witte, Daniel R.
  • Christensen, Cramer
  • Brandslund, Ivan
  • Appel, Emil V.
  • Scott, Robert A.
  • Luan, Jian' an
  • Langenberg, Claudia
  • Wareham, Nicholas J.
  • Pedersen, Oluf
  • Zorzano, Antonio
  • Florez, Jose C.
  • Hansen, Torben
  • Ferrer, Jorge
  • Mercader, Josep M.
  • Torrents, David
The reanalysis of existing GWAS data represents a powerful and cost-effective opportunity to gain insights into the genetics of complex diseases. By reanalyzing publicly available type 2 diabetes (T2D) genome-wide association studies (GWAS) data for 70,127 subjects, we identify seven novel associated regions, five driven by common variants (LYPLAL1, NEUROG3, CAMKK2, ABO, and GIP genes), one by a low-frequency (EHMT2), and one driven by a rare variant in chromosome Xq23, rs146662057, associated with a twofold increased risk for T2D in males. rs146662057 is located within an active enhancer associated with the expression of Angiotensin II Receptor type 2 gene (AGTR2), a modulator of insulin sensitivity, and exhibits allelic specific activity in muscle cells. Beyond providing insights into the genetics and pathophysiology of T2D, these results also underscore the value of reanalyzing publicly available data using novel genetic resources and analytical approaches., This work has been sponsored by the grant SEV-2011-00067 of Severo Ochoa Program, awarded by the Spanish Government. This work was supported by an EFSD/Lilly research fellowship. Josep M. Mercader was supported by Sara Borrell Fellowship from the Instituto Carlos III and Beatriu de Pinós fellowship from the Agency for Management of University and Research Grants (AGAUR). Sílvia Bonàs was FI-DGR Fellowship from FI-DGR 2013 from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya). This study makes use of data generated by the WTCCC. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113. This study also makes use of data generated by the UK10K Consortium, derived from samples from UK10K COHORT IMPUTATION (EGAS00001000713). A full list of the investigators who contributed to the generation of the data is available in www.UK10K.org. Funding for UK10K was provided by the Wellcome Trust under award WT091310. We acknowledge PRACE for awarding us to access MareNostrum supercomputer, based in Spain at Barcelona. The technical support group, particularly Pablo Ródenas and Jorge Rodríguez, from the Barcelona Supercomputing Center is gratefully acknowledged. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 667191. Mercè Planas-Fèlix is funded by the Obra Social Fundación la Caixa fellowship under the Severo Ochoa 2013 program. Work from Irene Miguel-Escalada, Ignasi Moran, Goutham Atla, and Jorge Ferrer was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre, the Wellcome Trust (WT101033), Ministerio de Economía y Competitividad (BFU2014-54284-R) and Horizon 2020 (667191). Irene Miguel-Escalada has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska–Curie grant agreement No 658145. We acknowledge Prof. Giulio Cossu (Institute of Inflammation and Repair, University of Manchester) for providing the muscle myoblast cell line. We also acknowledge the InterAct and SIGMA Type 2 Diabetes Consortia for access to the data to replicate the rs146662075 variant. A full list of the investigators of the SIGMA Type 2 Diabetes and the InterAct consortia is provided in Supplementary Notes 3 and 4. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk). This research has been conducted using the UK Biobank Resource (application number 16803). We also acknowledge Bianca C. Porneala, MS for his technical assistance in the collection and curation of the genotype and phenotype data from Partners Biobank. We also thank Marcin von Grotthuss for their support for uploading the summary statistics data to the Type 2 Diabetes Genetic Portal (AMP-T2D portal). Finally, we thank all the Computational Genomics group at the BSC for their helpful discussions and valuable comments on the manuscript., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

TIGER: The gene expression regulatory variation landscape of human pancreatic islets

  • Alonso, Lorena
  • Piron, Anthony
  • Morán, Ignasi
  • Guindo Martínez, Marta
  • Bonàs Guarch, Sílvia
  • Royo, Romina
  • Puiggròs, Montserrat
  • Amela, Ramon
  • Mercader, Josep M.
  • Torrents, David
Genome-wide association studies (GWASs) identified hundreds of signals associated with type 2 diabetes (T2D). To gain insight into their underlying molecular mechanisms, we have created the translational human pancreatic islet genotype tissue-expression resource (TIGER), aggregating >500 human islet genomic datasets from five cohorts in the Horizon 2020 consortium T2DSystems. We impute genotypes using four reference panels and meta-analyze cohorts to improve the coverage of expression quantitative trait loci (eQTL) and develop a method to combine allele-specific expression across samples (cASE). We identify >1 million islet eQTLs, 53 of which colocalize with T2D signals. Among them, a low-frequency allele that reduces T2D risk by half increases CCND2 expression. We identify eight cASE colocalizations, among which we found a T2D-associated SLC30A8 variant. We make all data available through the TIGER portal (http://tiger.bsc.es), which represents a comprehensive human islet genomic data resource to elucidate how genetic variation affects islet function and translates into therapeutic insight and precision medicine for T2D., This work has been supported by the European Union’s Horizon 2020 research and innovation program T2Dsystems under grant agreement no. 667191 . L.A. was supported by grant BES-2017-081635 of the Severo Ochoa Program, awarded by the Spanish government . I.M. was supported by the FJCI-2017-31878 Juan de la Cierva grant, awarded by the Spanish government . Work in the Cnop and Eizirik labs was further supported by the Fonds National de la Recherche Scientifique (FNRS), the Brussels Region Innoviris project DiaType , and the Walloon Region SPW-EER Win2Wal project BetaSource, Belgium . D.L.E. is supported by a grant from the Welbio–FNRS , Belgium. P.M., L.G., D.L.E., and M.C. are supported by the Innovative Medicines Initiative 2 Joint Undertaking Rhapsody , under grant agreement no. 115881 , which is supported by the European Union’s Horizon 2020 research and innovation programme, EFPIA and the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097 . J.M.M. is supported by American Diabetes Association Innovative and Clinical Translational Award 1-19-ICTS-068 . J.C. is supported by an Expanding Excellence in England Award from Research England . H.M., J.L.S.E., and L.E. are supported by the Swedish Strategic Research Foundation ( IRC15-0067 ). A.L.G. is a Wellcome Trust Senior Fellow in Basic Biomedical Science. This work was funded in Oxford and Stanford by the Wellcome Trust ( 095101 , 200837 , 106130 , and 203141 [all to A.L.G.]) and the NIH ( U01-DK105535 and U01-DK085545 [A.L.G.]). The research was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (A.L.G.). I.M.-E. was supported by the EFDS/Novo Nordisk Rising Star Programme . Work in the Ferrer lab was supported by the Imperial College London Research Computing Service , the NIHR Imperial BRC , and the Centre for Genomic Regulation (CRG) genomics facility , and grants from Ministerio de Ciencia e Innovación ( BFU2014-54284-R and RTI2018-095666-B-I00 ), the Medical Research Council ( MR/L02036X/1 ), the Wellcome Trust Senior Investigator Award ( WT101033 ), and the European Research Council Advanced Grant ( 789055 ). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. The technical support group from the Barcelona Supercomputing Center is gratefully acknowledged. Finally, we thank the entire Computational Genomics group at the BSC for their helpful discussions and valuable comments on the manuscript. We also acknowledge Cristian Opi and Laia Codó from the Barcelona Supercomputing Center for excellent website design and allocation of technical support and Isabelle Millard and Anyishaï Musuaya from the ULB Center for Diabetes Research for excellent technical and experimental support., Peer Reviewed, "Article signat per 30 autors/es: Lorena Alonso, Anthony Piron, Ignasi Morán, Marta Guindo-Martínez, Sílvia Bonàs-Guarch, Goutham Atla, Irene Miguel-Escalada, Romina Royo, Montserrat Puiggròs, Xavier Garcia-Hurtado, Mara Suleiman, Lorella Marselli, Jonathan L.S. Esguerra, Jean-Valéry Turatsinze, Jason M. Torres, Vibe Nylander, Ji Chen, Lena Eliasson, Matthieu Defrance, Ramon Amela, MAGIC24, Hindrik Mulder, Anna L. Gloyn, Leif Groop, Piero Marchetti, Decio L. Eizirik, Jorge Ferrer, Josep M. Mercader, Miriam Cnop, David Torrents", Postprint (published version)
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Human Pancreatic ß Cell lncRNAs Control Cell-Specific Regulatory Networks

  • Akerman, Ildem
  • Tu, Zhidong
  • Beucher, Anthony
  • Rolando, Delphine M. Y.
  • Sauty-Colace, Claire
  • Benazra, Marion
  • Nakic, Nikolina
  • Yang, Jialiang
  • Wang, Huan
  • Pasquali, Lorenzo|||0000-0003-2423-1826
  • Moran, Ignasi
  • Garcia Hurtado, Javier
  • Castro, Natalia
  • Gonzalez Franco, Roser
  • Stewart, Andrew F.
  • Bonner, Caroline
  • Piemonti, Lorenzo|||0000-0002-2172-2198
  • Berney, Thierry
  • Groop, Leif|||0000-0002-0187-3263
  • Kerr-Conte, Julie
  • Pattou, Francois
  • Argmann, Carmen
  • Schadt, Eric
  • Ravassard, Phillipe
  • Ferrer, Jorge|||0000-0002-5959-5729
Recent studies have uncovered thousands of long non-coding RNAs (lncRNAs) in human pancreatic ß cells. ß cell lncRNAs are often cell type specific and exhibit dynamic regulation during differentiation or upon changing glucose concentrations. Although these features hint at a role of lncRNAs in ß cell gene regulation and diabetes, the function of b cell lncRNAs remains largely unknown. In this study, we investigated the function of b cell-specific lncRNAs and transcription factors using transcript knockdowns and co-expression network analysis. This revealed lncRNAs that function in concert with transcription factors to regulate ß cell-specific transcriptional networks. We further demonstrate that the lncRNA PLUTO affects local 3D chromatin structure and transcription of PDX1, encoding a key ß cell transcription factor, and that both PLUTO and PDX1 are downregulated in islets from donors with type 2 diabetes or impaired glucose tolerance. These results implicate lncRNAs in the regulation of ß cell-specific transcription factor networks.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An integrated multi-omics approach identifies the landscape of interferon-α-mediated responses of human pancreatic beta cells

  • Colli, Maikel L.|||0000-0002-2200-4761
  • Ramos Rodríguez, Mireia|||0000-0001-8083-2445
  • Nakayasu, Ernesto S.|||0000-0002-4056-2695
  • Alvelos, Maria I.
  • Lopes, Miguel
  • Hill, Jessica L. E.
  • Turatsinze, Jean-Valery|||0000-0001-9492-6274
  • Coomans de Brachène, Alexandra
  • Russell, Mark A.
  • Raurell Vila, Helena|||0000-0003-1196-836X
  • Castela, Angela
  • Juan-Mateu, Jonàs
  • Webb-Robertson, Bobbie-Jo M.
  • Krogvold, Lars
  • Dahl-Jorgensen, Knut
  • Marselli, Lorella|||0000-0002-6698-2962
  • Marchetti, Piero
  • Richardson, Sarah J.|||0000-0002-1160-6062
  • Morgan, Noel G.|||0000-0003-1537-8113
  • Metz, Thomas O.|||0000-0001-6049-3968
  • Pasquali, Lorenzo|||0000-0003-2423-1826
  • Eizirik, Décio L.|||0000-0003-2453-5889
Interferon-α (IFNα), a type I interferon, is expressed in the islets of type 1 diabetic individuals, and its expression and signaling are regulated by T1D genetic risk variants and viral infections associated with T1D. We presently characterize human beta cell responses to IFNα by combining ATAC-seq, RNA-seq and proteomics assays. The initial response to IFNα is characterized by chromatin remodeling, followed by changes in transcriptional and translational regulation. IFNα induces changes in alternative splicing (AS) and first exon usage, increasing the diversity of transcripts expressed by the beta cells. This, combined with changes observed on protein modification/degradation, ER stress and MHC class I, may expand antigens presented by beta cells to the immune system. Beta cells also up-regulate the checkpoint proteins PDL1 and HLA-E that may exert a protective role against the autoimmune assault. Data mining of the present multi-omics analysis identifies two compound classes that antagonize IFNα effects on human beta cells.